ixlayer, a digital diagnostic at-home testing company, is partnering with CVS Health to produce four over-the-counter self-diagnostic tests for the pharmacy giant.
San Francisco-based ixlayer will provide the technology platform and logistics network for Vitamin D, Lyme disease, sexually-transmitted infections and thyroid function tests available in CVS stores later this fall under the national pharmacy chain’s own brand, CVS Health. After purchasing a test, kits are shipped back to an approved lab and results are delivered to patients online.
The rollout will begin online and in around 1,000 stores across 35 states, said Pouria Sanae, ixlayer’s CEO. He said the partnership could expand to additional stores if the tests show promise in retail stores.
According to Sanae, the tests will not be available in New York, New Jersey and Rhode Island due to state regulations.
“Prior to CVS, we have done 1,100 programs,” Sanae said. “So, this becomes yet another program for us with a large brand. It's not in the DNA of these organizations to do this, and eventually they will all have it.”
The news follows CVS Health’s decision last month to acquire home health provider, Signify Health for around $8 billion in cash.
Both moves signal a shift in the company’s view of how home health bridges patient access and offers additional revenue streams outside of its brick-and-mortar pharmacies.
Sanae said abnormal results will prompt users to have a telehealth consultation. Before COVID, he said the target demographic for the tests were younger patients curious about their health.
“Pre-COVID, everybody that was doing this was what we call an early adopter,” Sanae said. “There is a bigger focus on preventative care today and what we had pre-COVID.”
After the Signify Health acquisition, CVS Health’s chief medical officer, Dr. Sree Chagutruru, said the company was looking for opportunities in primary care, primary care enablement and home care services.